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ABSTRACT
Background. Failure of chemoradiotherapy (CRT) for
anal squamous cell carcinoma (SCC) results in persistent or
recurrent anal SCC. Treatment with salvage
abdominoperineal resection (APR) can potentially achieve
cure. The aims of this study are to analyze oncological and
surgical outcomes of our 30-year experience with salvage
APR for anal SCC after failed CRT and identify prognostic
factors for overall survival (OS).
Methods. All consecutive patients who underwent salvage
APR between 1990 and 2016 for histologically confirmed
persistent or recurrent anal SCC after failed CRT were
retrospectively analyzed.
Results. Forty-seven patients underwent salvage APR for
either persistent (n = 24) or recurrent SCC (n = 23). Median
OS was 47 months [95% confidence interval (CI)
10.0–84.0 months] and 5-year survival was 41.6%, which
did not differ significantly between persistent or recurrent
disease (p = 0.551). Increased pathological tumor size (p\
0.001) and lymph node involvement (p = 0.014) were
associated with impaired hazard for OS on multivariable
analysis, and irradical resection only (p = 0.001) on uni-
variable analysis. Twenty-one patients developed local
recurrence after salvage APR, of whom 8 underwent repeat
salvage surgery and 13 received palliative treatment.
Median OS was 9 months (95% CI 7.2–10.8 months) after
repeat salvage surgery and 4 months (95% CI 2.8–5.1
months) following palliative treatment (p = 0.055).
Conclusions. Salvage APR for anal SCC after failed CRT
resulted in adequate survival, with 5-year survival of
41.6%. Negative prognostic factors for survival were
increased tumor size, lymph node involvement, and irrad-
ical resection. Patients with recurrent anal SCC after
salvage APR had poor prognosis, irrespective of perfor-
mance of repeat salvage surgery, which never resulted in
cure.
Squamous cell carcinoma (SCC) of the anal canal is a
relatively rare malignancy, but its incidence has increased
over the last few years.1 Currently, chemoradiotherapy
(CRT) is standard of care for anal cancer, resulting in
superior local control compared with radiotherapy alone
with 5-year survival rates of 60–80%.2–8 CRT leads to
preservation of the anal sphincter by avoiding surgery.
Unfortunately, CRT fails in 20–30% of patients, resulting
in persistent (10–15%) or local recurrent disease
(10–15%).2–7,9
Salvage abdominoperineal resection (APR) is often the
only option for patients with persistent or recurrent anal
SCC to achieve durable local control and survival. Several
institutes have reported case series on this topic. However,
due to heterogeneity in treatment protocols, results on
patient outcomes vary widely.10–20 Our institute has a well-
established protocol for treatment of anal SCC, which has
changed little in the last three decades. The aims of the
present study are to analyze the results of a 30-year
experience with salvage APR for recurrent and persistent
anal SCC after failed CRT in a large single-center cohort
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and to identify prognostic factors for overall survival. In
addition, outcomes of patients treated for local recurrence
developed after primary salvage APR for persistent or
recurrent SCC were also analyzed. To the best of the
authors’ knowledge, results of repeat surgery for treatment
of local recurrence after salvage APR have never been
previously studied.
PATIENTS AND METHODS
Data of all consecutive patients who underwent salvage
APR with curative intent for histologically confirmed
persistent or recurrent anal SCC between 1990 and 2016 at
the Erasmus MC Cancer Institute, a tertiary referral center
in The Netherlands, were retrospectively analyzed. Patient
demographics, perioperative variables, tumor characteris-
tics, neoadjuvant therapy, short- and long-term outcomes,
and postoperative mortality and morbidity were collected
from medical records, the municipality register, and gen-
eral practitioners. All patients were followed up by our
institute; last update of follow-up was 22 January 2018.
The present study was approved by the Erasmus MC local
medical ethics committee (registration number MEC-2017-
448).
Primary Treatment
All primary malignancies were initially treated with
radiotherapy, and the majority (78.7%) also received con-
comitant chemotherapy. Radiotherapy was administered
with median dose of 60 Gy [interquartile range (IQR)
60–60 Gy], and chemotherapy was administered in the first
four days of the first week [5-fluorouracil (1000 mg/m2)
and mitomycin C (10 mg/m2)]. Patients with histologically
proven anal SCC within 6 months after the last day of
radiotherapy, or patients with incomplete response, were
classified as having persistent disease. Initial complete
responders to (chemo)radiotherapy, who were diagnosed
with biopsy-proven recurrent anal SCC, after 6 months or
more since the last day of radiotherapy, were classified as
having recurrent disease.
Staging
Tumor stage was assessed by physical examination and
radiologic imaging according to the American Joint Com-
mittee on Cancer (AJCC) tumor–node–metastasis (TNM)
staging system (7th edition) for cancer of the anal canal.
Nodal stage was assessed by pelvic magnetic resonance
imaging (MRI), and suspicious inguinal lymph nodes were
biopsied. Computed tomography (CT) scans of the chest
and abdomen were used to confirm absence of metastatic
disease prior to surgery.
Surgery
All patients deemed eligible for complete, curative
resection underwent salvage APR. Multivisceral resection
was performed if necessary. If possible, omentoplasty was
performed to fill the pelvis. Primary closure of the perineal
defect was routinely performed up to 1999, and if this was
not feasible, the open wound was packed for healing by
secondary intention. From 2000 onwards, the perineal
defect was reconstructed with either a vertical rectus
abdominis myocutaneous (VRAM) or gracilis muscle
flap.21,22 Inguinal lymph node dissection was performed in
case of biopsy-proven positive lymph nodes. Postoperative
complications were graded according to the Dindo–Clavien
classification.23 Local recurrence after salvage APR was
defined as any local recurrence after salvage APR,
regardless of whether the indication for salvage APR was
for persistent or recurrent anal SCC.
Statistics
Survival analysis was performed by Kaplan–Meier
method, and comparisons were made using log-rank tests.
Survival was calculated from day of APR until data of
death or last follow-up. Survival rates for recurrence after
salvage APR were calculated from date of diagnosis of
recurrent anal SCC until death or last follow-up. Cox
proportional-hazard models were constructed to identify
prognostic factors in univariable and multivariable analy-
sis. Mann–Whitney U and chi-squared test were performed
as appropriate. Covariables with a trend towards signifi-
cance (p\0.100) were selected for multivariable analysis,
with a maximum of three considering the number of
events. Two-sided p-values \ 0.05 were considered sta-
tistically significant. Statistical analysis was performed
using IBM SPSS Statistics version 24.0.0 for Windows
(IBM Corp, Armonk, New York, USA).
RESULTS
Forty-seven consecutive patients underwent salvage
APR for anal SCC between 1990 and 2016. Patient char-
acteristics are depicted in Table 1.
Surgical Results
Indications for surgery were either persistent (n = 24;
48.9%) or recurrent disease (n = 23; 51.1%). Median time
between the last day of (chemo)radiotherapy and date of
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surgery was 5 months (IQR 4–7 months) for patients with
persistent disease and 15 months (IQR 9.5–37.5 months)
for patients with recurrent disease. APR without additional
resections was performed in 35 patients, APR with poste-
rior vaginal wall resection in 4 patients, posterior
exenteration in 6 patients (including vulvectomy in 2
patients), and total pelvic exenteration in 2 patients. Other
additional procedures were partial sacrectomy (n = 2),
synchronous inguinal lymph node dissection (n = 2), and
intraoperative radiotherapy (IORT, n = 2). Omentoplasty
was performed in 33 patients. One patient had two lesions
TABLE 1 Patient and tumor characteristics before and after
abdominoperineal resection (N = 47)
N %
Gender
Male 27 57.4
Female 20 42.6
Age
At time of diagnosis primary 53 (46–66)*
At time of operation 56 (48–66)*
Clinical tumor stage
T1 8 17.0
T2 20 42.6
T3 13 27.7
T4 6 12.8
Clinical nodal stage
N0/Nx 40 85.1
N1 5 10.6
N2 2 4.3
Clinical Metastasis stage
M0 45 95.7
M? 2 4.3
Histology
Squamous cell carcinoma 47 100
Pretreatment
Radiotherapy 47 100
Mean dose Gy 60 (60–60)*
Concomitant chemotherapy
5-FU Mitomycin C 36 76.6
5-FU only 1 2.1
No chemotherapy 10 21.3
Indication for surgery
Persistent disease 24 48.9
Recurrent disease 23 51.1
Time interval radiotherapy and surgery (in
months)
Persistent disease 5 (4–7)*
Recurrent disease 15.0
(9.5–37.5)*
Surgical procedure
APR 35 74.5
APR and posterior vaginal wall 4 8.5
Posterior exenteration 4 8.5
Total pelvic exenteration 2 4.3
Posterior exenteration and vulvectomie 2 44.3
Additional procedures
Partial sacrectomy 2 4.3
Synchronous ILND 2 4.3
Omentoplasty 33 70.2
IORT 2 4.3
TABLE 1 continued
N %
Wound closure and/or reconstruction
Primary closure 10 21.3
Wound left open 1 2.1
VRAM-flap 31 66.0
Gracilis flap 3 6.4
Pudendus flap 1 2.1
Gluteal flap 1 2.1
Operating time
Minutes 378.6 ± 129.9**
Pathological tumor size
Maximum diameter (millimeter) 30.0 (20.0–48.3)*
Pathological nodal stage
N0/Nx 41 87.2
N1 2 4.3
N2 4 8.5
Pathological metastases stage
M0/Mx 43 91.5
M1 4 8.5
Vasoinvasion
Yes 11 23.3
No 18 38.3
Unknown 18 38.3
Perineural growth
Yes 14 29.8
No 15 31.3
Unknown 18 38.3
Pathological resection margins
R0 38 80.9
R1 8 17.0
R2 1 2.1
*Median and interquartile range, **Mean and standard deviation
APR abdominoperineal resection, IORT intra-operative radiotherapy,
VRAM vertical rectus abdominus muscle, ILND Inguinal lymph node
dissection, 5-FU 5-fluorouracil
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in the liver suspicious for metastases, which were
histopathologically confirmed by frozen section. Salvage
APR was performed, but the liver metastases were not
resected. Until 1999, primary perineal closure was per-
formed in seven patients, one open wound was packed for
secondary healing, and one gluteal transposition flap was
performed for reconstruction. In 38 patients treated from
2000 onwards, primary perineal closure was performed
three times, while a locoregional flap for perineal closure
was used 35 times [VRAM flap (n = 31), gracilis muscle
flap (n = 3), and bilateral pudendal flap (n = 1)]. Surgical
characteristics are presented in Table 1. Radical resection
(R0) was achieved in 38 patients (80.9%), microscopically
irradical resection (R1) in 8 patients (17.0%), and macro-
scopically irradical resection (R2) in 1 patient (2.1%). One
patient had liver metastases, and three patients had inguinal
lymph node metastases. Tumor characteristics are listed in
Table 1.
Mortality and Morbidity
None of the patients died within 30 days of surgery.
Within 2 months, there was one case of euthanasia due to
unbearable suffering from severe wound infection and no
perspective of cure considering confirmed liver metastases.
The majority of patients (n = 33; 70.3%) experienced no or
minor complications (Dindo–Clavien B 2), and 14 patients
(29.7%) developed major complications (Dindo–Clavien
C 3). Mortality and morbidity are displayed in Table 2. Six
out of 10 patients with primary closure of the perineal
defect and 9 out of 36 patients with muscle flap recon-
struction (MFR) experienced perineal wound
complications. Nine patients required surgery for perineal
wound complications. The latter were treated with
debridement with (n = 5) or without vacuum-assisted clo-
sure therapy (n = 2) and muscle flap necrosectomy
followed by repeat reconstruction (n = 2). Median time
between last day of radiotherapy and surgery did not sig-
nificantly influence perineal wound complications (p =
0.909). The proportion of patients with perineal wound
complications was lower in patients treated with MFR
(25%; 9/36) compared with patients treated without MFR
(54.5%; 6/11), however this was not significant (p = 0.066).
Survival
Median follow-up time was 80 months (95% CI
68.6–91.4 months). At last follow-up, 19 patients (40.4%)
were alive. Median overall survival (OS) was 47 months
(95% CI 10.0–84.0 months), and the estimated 5-year
survival rate was 41.6%. Survival curves did not differ
significantly between patients with persistent versus
recurrent disease (5-year survival rate 40.4 vs. 41.7%,
respectively; p = 0.551). Survival curves are shown in
Fig. 1. On both univariable and multivariable analysis,
increased pathological tumor size (p\0.001) and positive
lymph nodes (p = 0.014) were significantly associated with
worse OS. Irradical resection was only significantly asso-
ciated on univariable analysis (p = 0.001) but not on
multivariable analysis (p = 0.087). Analyses are presented
in Table 3, and the influence on survival in Fig. 2.
Recurrence after Salvage APR
The overall rate of disease recurrence after salvage APR
was 55.3%. Twenty-one patients (44.7%) developed local
recurrence after salvage APR, including 13 patients with
simultaneous locoregional recurrence or distant metastases
[inguinal lymph node (n = 7), liver (n = 2), adrenal gland
(n = 1), retroperitoneal lymph nodes (n = 1), peritoneal
carcinomatosis (n = 1), and cervical lymph node ? liver
metastasis (n = 1)]. Five patients developed distant
metastases or locoregional recurrence only [inguinal lymph
TABLE 2 Mortality, morbidity, and perineal wound complications
N %
Mortality
\ 30 days after surgery 0 0
During hospital admission 1 2.1
Dindo-Clavien
None 17 36.2
Dindo 1 6 12.8
Dindo 2 10 21.3
Dindo 3A 1 2.1
Dindo 3B 10 21.3
Dindo 4 3 6.4
Dindo 5 0 0
Major complications
Pulmonary embolism 1 2.1
Aspiration pneumonia 2 4
Gastric ulcer bleeding 1 2.1
Major complications requiring surgery
Stoma necrosis 1 2.1
Abdominal wound necrosis 1 2.1
Fascia dehiscence 1 2.1
Perineal wound complications MFR
(N = 36)
No MFR
(N = 11)
Additional muscle flap reconstruction 1 1
Vacuum assisted therapy 3 2
Wound complication treated conservative 4 3
Wound complication requiring debridement 2 0
Perineal hernia 1 1
MFR muscle flap reconstruction
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node (n = 2), retroperitoneal lymph nodes (n = 1), hilar
lymph nodes (n = 1), liver metastases (n = 1)]. Median OS
for patients with local recurrence and/or distant metastases
after salvage APR was 12 months (95% CI 8.3–15.7
months). Median local-recurrence-free survival after sal-
vage APR (LRFS) was not reached. The estimated 5-year
LRFS after salvage APR was 51.1%. None of the patients
developed local recurrence after 42 months from salvage
APR. Three patients received postoperative chemotherapy
for metastatic disease, and none of the patients received
standard adjuvant chemotherapy.
Eight patients with local recurrence after salvage APR
underwent repeat salvage surgery by extensive local exci-
sion, including additional inguinal lymph node dissection
(n = 2), liver metastases resection (n = 1), and cervical
lymph node dissection (n = 1).
Thirteen patients underwent palliative treatment for
local recurrence after salvage APR, including fistula
resection (n = 2), radiotherapy in combination with
hyperthermia (n = 2), and chemotherapy for metastatic
disease (n = 2), while seven patients received best sup-
portive care only. Median OS for all patients with local
recurrence after salvage APR, calculated from date of
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diagnosis of local recurrence, was 7 months (95% CI
1.0–13.0 months). The 1-year survival rate was 19.0%, and
all patients died within 15 months except for one patient,
who had undergone repeat salvage surgery and was still
alive at last follow-up of 22 months.
There was no significant difference (p = 0.055) in sur-
vival of patients with local recurrence after salvage APR
treated with repeat salvage surgery, with median OS of 9
months (95% CI 7.2–10.8 months), compared with patients
with palliative treatment, with median OS of 4 months
(95% CI 2.8–5.1 months).
DISCUSSION
The present study describes the results of salvage APR
for SCC of the anal canal after failure of initial primary
therapy in 47 patients. Overall estimated 5-year survival
was 41.6%. Negative prognostic factors were increased
pathological tumor size and lymph node involvement on
multivariable analysis, and positive resection margin only
on univariable analysis. Type of local failure did not affect
survival. The overall local recurrence rate after salvage
APR was 44.7%. None of the patients who developed local
recurrence after salvage APR could be cured, and all had
poor prognosis.
Although surgery has been replaced by CRT for primary
treatment of SCC of the anal canal, salvage APR has
remained the gold standard for patients with persistent
disease or local recurrent disease after failed CRT. Due to
the relative rarity of the procedure for this indication, most
published series consist of only a small number of patients
treated over a long period of time, and are therefore prone
to a certain degree of bias. We present herein a rather
homogeneous group of patients. All patients were treated
with an adequate radiation dose of [ 45 Gy, and all but
eight patients received the standard protocol of 60 Gy. This
in contrast to some other published series where the study
population was treated with a wide range of radiation
doses.9–11,16
The percentages of radical resection and 30-day postop-
erative mortality are comparable to previous studies.9,13,24–27
Outcome measures of complications after salvage APR varied
widely in other studies, preventing adequate comparison.
However, in the current study, surgical reinterventions were
slightly more common (25.5%) than the range reported by
others (12–20%).13,24–26 In this study, 31.9% of patients
experienced perineal complications, while others reported
perineal complications in 22–50% of patients, regardless of
use of muscle flap reconstruction.9,13,16,25,27 We could not
identify a group prone to perineal complications based on time
between radiotherapy and surgery or use of muscle flap
reconstruction, possibly due to small numbers.
The 5-year OS in this study of 41.6% lies within the
range of 23–69% reported by other authors. Survival of
patients with persistent disease did not differ significantly
from that of patients with recurrent disease, which is also in
agreement with results published previ-
ously,10,11,14,15,17,19,28 although some studies did report
poorer survival rates in patients with persistent compared
with recurrent disease.10,16 This could be explained by
more aggressive behavior of tumor cells in persistent dis-
ease or fast regrowth. However, other studies reported
significantly worse survival in patients with recurrent dis-
ease, which could not be explained clearly.29,30
We found that increased pathological tumor size, lymph
node involvement, and positive resection margins
adversely affected survival, which is in concordance with
most other series (Appendix 1).9–11,13–15,17,24,25,28,30–32
Although not identified on multivariable analysis in the
present study, positive resection margin seems to remain
TABLE 3 Univariable and multivariable survival analysis for overall survival of squamous cell carcinoma
Univariable P value Multivariable P value
Hazard ratio [95% CI] Hazard ratio [95% CI]
Male versus female 1.150 [0.536–2.466] 0.720 – –
Age at time of operation 1.021 [0.986–1.058] 0.239 – –
CTxRTx versus RTx 0.884 [0.332–2.351] 0.805 – –
Recurrent disease versus persistent disease 0.794 [0.794–1.709] 0.556 – –
Multivisceral resection 1.169 [0.524–2.608] 0.704 – –
Irradical resection (R1/R2) 4.056 [1.746–9.423] 0.001 2.786 [0.862–9.005] 0.087
Node positive (N1/N2) 3.228 [1.255–8.302] 0.015 4.445 [1.356–14.563] 0.014
Metastasis positive (M1) 2.603 [0.878–7.712] 0.084 – –
Vasoinvasion 2.081 [0.795–5.679] 0.144 – –
Perineural growth 2.702 [0.973–7.504] 0.056 – –
Pathological tumor size (maximum diameter in mm) 1.039 [1.023–1.055] \ 0.001 1.036 [1.018–1.054] \ 0.001
CTxRTx chemoradiotherapy, RTx radiotherapy
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the most common factor negatively affecting survival.
These findings emphasize the importance of achieving
negative resection margins, which can sometimes only be
achieved by aggressive multivisceral resection or multi-
disciplinary treatment.
Recently, Hallemeier et al.30 reported a multidisci-
plinary approach, including reirradiation with or without
concomitant chemotherapy and IORT, in a small group of
patients with persistent or recurrent anal cancer. Only 21%
developed recurrence within the reirradiated area. The
5-year OS was 23%, but they specifically treated patients
with expected narrow or positive resection margins.30 In
the present study, only two patients received IORT, and
none received reirradiation prior to salvage surgery,
because of the high-dose radiotherapy used as primary
treatment. Wright et al.33 retrospectively analyzed 14
patients with locoregional recurrent anal SCC who under-
went salvage surgery and IORT. Addition of IORT was not
associated with locoregional control or survival benefit and
did not compensate for positive surgical margins.33 Reir-
radiation and IORT could potentially decrease local
recurrence rate, but this remains unclear.
Currently there is no role for standard adjuvant
chemotherapy, however the combination of cisplatin and
5-fluorouracil (5-FU) is the gold standard in metastatic
disease, with an overall response rate of 60%.34,35 Eng
et al.36 showed a prolonged OS for multidisciplinary
management with systemic chemotherapy and intervention
compared with palliative chemotherapy only in patients
with unresectable and metastatic anal SCC.36 In the present
study, three patients received postoperative chemotherapy
without additional intervention. Therefore, we could not
clearly assess the effect on OS. Multidisciplinary treatment
for unresectable and metastatic anal SCC can potentially
lead to prolonged OS.
To our knowledge, this is the first study to present data on
treatment of recurrent anal SCC after failed CRT for primary
anal SCC and salvage APR for recurrent/persistent anal SCC.
Alamri et al.27 and Correa et al.24 only reported survival for
these patients. Some patients with local recurrence after sal-
vage APR also had distant metastases or locoregional
recurrence, and type of surgery was not protocolled as it is for
the primary salvage APR. On the other hand, our results
clearly show that recurrence after salvage APR has poor
prognosis, regardless of the treatment. Palliative surgery may
still be considered for some patients, especially those with
pain. Cure, however, does not seem to be possible.
This study is limited by its retrospective nature and the
small number of patients collected over a long time period.
Patients with persistent or recurrent disease have different
tumor biology, and mixing these cases could affect the
outcomes of salvage APR. Advances in diagnostic imaging
and treatment were made during the study period and likely
contributed to heterogeneity in our study population and
outcomes.
CONCLUSIONS
The results of the present study show that salvage APR
for patients with SCC of the anal canal after failed CRT
provides adequate long-term survival and local control.
Prognostic factors for survival were advanced tumor stage,
lymph node involvement, and positive resection margins.
Patients with recurrent anal SCC after salvage APR had
poor prognosis irrespective of performance of repeat sal-
vage surgery, which never resulted in cure.
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APPENDIX 1: OVERVIEW OF CURRENT LITERATURE
Ref. Year of publication No. of patients 5-Year OS (%) Prognostic factors for OS after salvage APR
Zelnick et al.20 1992 9 24 Not identified or not mentioned
Ellenhorn et al.11 1993 38 44 Nodal disease
Tumor fixed to lateral pelvic wall
Involvement of perirectal fat
Longo et al.6 1994 34 23–53 Stage
Method of treatment
Pocard et al.37 1998 21 33 Not identified or not mentioned
Allal et al.29 1999 26 45 Not identified or not mentioned
Smith et al.18 2001 22 33 Not identified or not mentioned
Van der Wal et al.19 2001 17 47 Not identified or not mentioned
Nilsson et al.16 2002 35 52 Persistent disease
Akbari et al.10 2004 62 33 Tumor size[ 5 cm
Local extent
Nodal disease
Positive resection margins
Ghouti et al.12 2005 36 69 Not identified or not mentioned
Ferenschild et al.38 2005 18 30 Not identified or not mentioned
Renehan et al.9 2005 73 40 Positive resection margins
Mullen et al.15 2006 31 64 Nodal disease
\ 55 Gy radiotherapy dose
Stewart et al.31 2007 22 24–48 Tumor differentiation
Positive resection margins
Schiller et al.17 2007 40 39 Tumor size
Sex (male)
Mariani et al.14 2008 83 57 Age[ 55 years
Nodal disease
T3–4 tumor
Local extent
Sunesen et al.25 2009 49 61 Positive resection margins
Eeson et al.32 2011 51 29 Positive resection margins
Correa et al.24 2012 111 25 Nodal disease
Positive resection margin
Perineural and/or lymphovascular invasion
Lefevre et al.13 2012 105 61 T3–T4 status
Positive resection margins
Metastatic disease
Hallemeier et al.30 2014 32 23 Recurrent disease versus persistent disease
Positive resection margins
Viable disease in resection specimen
Alamri et al.27 2016 27 78 None identified
Pesi et al.26 2017 20 37 None published
Present study 2017 47 41 Increased pathological tumor size (mm)
– Nodal disease
– Positive resection margins
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